Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.

Biological & pharmaceutical bulletin - 1 Jan 2021

Hu Shengquan, Liu Jing, Chen Sikang, Gao Jian, Zhou Yubo, Liu Tao, Dong Xiaowu

Abstract excerpt

FMS-like tyrosine kinase 3 (FLT3) plays a very important role in regulating the proliferation, differentiation and survival of normal hematopoietic stem cells. Internal tandem duplications of the FLT3 gene (FLT3-ITD) mutations are present in 25% of all acute myeloid leukemia (AML) patients and are frequently associated with adverse clinical outcomes. Therefore, FLT3-ITD is a promising target for the treatment of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to fms-Like Tyrosine Kinase 3

Share to Leukemia, Myeloid, Acute

Share to Molecular Docking Simulation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-kit

Source

Identifiers

PMID: 34853270
DOI: 10.1248/bpb.b21-00579

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Discover Novel Covalent Inhibitors Targeting FLT3 through Hybrid Virtual Screening Strategy.PMID 34853270Read ↗

Identification of a dual FLT3 and MNK2 inhibitor for acute myeloid leukemia treatment using a structure-based virtual screening approach.Semantic proximity Read ↗

Structure-Guided Discovery and Characterization of Novel FLT3 Inhibitors for Acute Myeloid Leukemia TreatmentSemantic proximity Read ↗

In silico and in vitro study of FLT3 inhibitors and their application in acute myeloid leukemia.Semantic proximity Read ↗

Discovery of natural compounds as novel FMS-like tyrosine kinase-3 (FLT3) therapeutic inhibitors for the treatment of acute myeloid leukemia: an <i>in silico</i> approachSemantic proximity Read ↗

Identification of inhibitors targeting the FLT3-ITD mutation through 4D-QSAR, in vitro, and in silico.Semantic proximity Read ↗

Combined machine learning models, docking analysis, molecular dynamics and experimental validation for the rapid design of novel FLT3 inhibitors against AMLSemantic proximity Read ↗

A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations.Semantic proximity Read ↗

Discovery of benzimidazole-indazole derivatives as potent FLT3-tyrosine kinase domain mutant kinase inhibitors for acute myeloid leukemia.Semantic proximity Read ↗

Design and synthesis of selective FLT3 inhibitors via exploration of back pocket II.Semantic proximity Read ↗

The Structural Effect of FLT3 Mutations at 835th Position and Their Interaction with Acute Myeloid Leukemia Inhibitors: In Silico Approach.Semantic proximity Read ↗

Synthesis and biological evaluation of 4-(4-aminophenyl)-6-methylisoxazolo[3,4-b] pyridin-3-amine covalent inhibitors as potential agents for the treatment of acute myeloid leukemia.Semantic proximity Read ↗

Identification of novel tyrosine kinase inhibitors for drug resistant T315I mutant BCR-ABL: a virtual screening and molecular dynamics simulations study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.